CGRP Forum
Send to a colleague
Register  Login
Home   |   About   |   About CGRP   |   News   |   Hot Topics   |   Trials    |   Resources   |   Contact

In case you missed it

In the last three months, we have seen rapid regulatory approvals for Emgality (galcanezumab) in the US and EU, and for Ajovy (fremanezumab) in the US.

Catch up at:

Emgality (galcanezumab) receives EU approval in migraine prevention »

Emgality (galcanezumab) approved for migraine prevention in USA »

Ajovy (fremanezumab) wins US approval in migraine prevention »

With three anti-CGRP therapies now available to clinicians, Editor-in-Chief, Dr David Dodick, has written a very timely ‘Hot Topic’ on where these novel agents fit within the therapeutic options for migraine.

Catch up at:

Anti-CGRP therapy: where does it fit in our clinics? »

From two major conferences this Autumn, we reported latest results from CGRP inhibitor trials, including the PROMISE-1 study of eptinezumab, and novel insights from erenumab responder data.

Catch up at:

Eptinezumab acts fast and has sustained activity in episodic migraine »

Erenumab responder data may help set expectations for migraine frequency and disability with ongoing prophylaxis »

Further reports from the Autumn conferences focus on additional recent advances in understanding and treatment of migraine.

Catch up at:

12th European Headache Federation Congress »

17th Biennial Migraine Trust International Symposium »

For all the other recent migraine news featured on the CGRP Forum click here »

Becoming a member is easy

Members have free open access simply by registering online.
Facebook Like us on Facebook
For the latest updates, CGRP news and analysis.
Twitter Follow us on Twitter
Hot topics, news and conference reports.
Educational Partners and Supporters (others pending) Logos
© Copyright CGRP Forum 2018. Please click here to unsubscribe from future mailings.